Hospira Sterility Problems Cause Another Recall

News
Article

Fagron Sterile Services has voluntarily recalled three lots of Succinylcholine Chloride 20mg/mL 5mL syringe to the hospital/clinic level.

Fagron Sterile Services announced on June 23, 2017 that it is voluntarily recalling three lots of Succinylcholine Chloride 20mg/mL 5mL syringe to the hospital/clinic level because of sterility assurance concerns. The recalled product is manufactured by Hospira, a Pfizer company, and repacked by Fagron Sterile Services. The impacted lots were distributed nationwide.

During a routine simulation of its manufacturing process, Hospira detected microbial growth, prompting several recalls of a variety of products. The product is being recalled out of caution because, according to Hospira, patients may experience adverse events ranging from fever and chills to systemic invasive mycoses or systemic bacterial sepsis if contaminated product is administered. Neither Hospira or Fagron Sterile Services has, to date, received any reports of adverse events associated with the recalled product.

Succinylcholine Chloride Injection is used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is repacked by Fagron Sterile Services into 5mL doses of Succinylcholine Chloride 20mg/mL. Adverse events can be reported to FDA at www.fda.gov/medwatch/report.htm.

Source: FDA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments